Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$205.27 USD

205.27
595,091

+3.94 (1.96%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

Why Charles River (CRL) International Revenue Trends Deserve Your Attention

Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down

Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.

Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings

While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates

Charles River (CRL) delivered earnings and revenue surprises of 17.15% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings

Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.

Charles River's (CRL) RMS Growth Aids Amid FX Headwind

Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Charles River (CRL) Inks CDMO Deal With Gates Institutes

Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

Charles River (CRL) Partners to Reduce Animal Research Usage

Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.

Charles River (CRL) Launches Viral Vector Tech Transfer Program

Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.

Reasons to Hold Charles River (CRL) in Your Portfolio Now

Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.

Charles River (CRL) Banks on RMS Growth Amid Competition

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

Smart Beta ETF report for JSMD

Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock

Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y

Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.

Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Sotera Health Company (SHC) Misses Q1 Earnings and Revenue Estimates

Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ICLR vs. CRL: Which Stock Is the Better Value Option?

ICLR vs. CRL: Which Stock Is the Better Value Option?

Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates

Teladoc (TDOC) delivered earnings and revenue surprises of -4.26% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?